Drug Profile
Sotorasib - Amgen
Alternative Names: AMG-510; LUMAKRAS; LUMYKRASLatest Information Update: 23 Apr 2024
Price :
$50
*
At a glance
- Originator Amgen; Carmot Therapeutics
- Developer Amgen; BeiGene; REVOLUTION Medicines
- Class Antineoplastics; Piperazines; Pyridines; Pyridones; Pyrimidines; Small molecules
- Mechanism of Action KRAS protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Non-small cell lung cancer
- Phase III Colorectal cancer; Solid tumours
- Phase I/II Brain metastases; Pancreatic cancer
Most Recent Events
- 12 Apr 2024 Amgen withdraws a phase I pharmacokinetics trial (In volunteers) (PO) prior to enrolment as FDA and EMA agreed existing data are appropriate for approval and no further BE studies are required (NCT06061523)
- 15 Feb 2024 Amgen plans a phase III CodeBreak301trial for Colorectal cancer (Metastatic disease, Combination therapy, First-line therapy) in April 2024 (PO, Tablets) (NCT06252649)
- 06 Feb 2024 Amgen intends to submit regulatory application for KRAS G12C-mutated metastatic colorectal cancer in H1 2024